A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program

Authors

Griet Hoste (ORCID: https://orcid.org/0000-0002-4331-8663)
Natalija Dedić Plavetić (ORCID: https://orcid.org/0000-0003-0505-4756)
M. Zivanov
Michelino De Laurentiis (ORCID: https://orcid.org/0000-0001-9009-1572)
Xavier González (ORCID: https://orcid.org/0000-0002-5797-7037)
Marija Križić (ORCID: https://orcid.org/0000-0003-2411-6350)
Tajana Silovski (ORCID: https://orcid.org/0000-0002-4699-5432)
Ángel Guerrero‐Zotano (ORCID: https://orcid.org/0000-0003-0318-9120)
Jeanne Suissa
Olivia Dialla
F. Beghdad
Olivier Romano
Ana Luisa Jiménez

Institutions

University Hospital Centre Zagreb (HR)
University of Zagreb (HR)
Universitair Ziekenhuis Leuven (BE)
Instituto Oncológico Dr. Rosell (ES)
Fundación Instituto Valenciano de Oncología (ES)
Complejo Hospitalario de Jaén (ES)
Esteve Química (Spain) (ES)
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT)
Pierre Fabre (France) (FR)

Publication Details

Journal: Oncology and Therapy
Published: 2025-10-29
DOI: https://doi.org/10.1007/s40487-025-00392-w
Primary Topic: HER2/EGFR in Cancer Research
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program

Griet Hoste, Natalija Dedić Plavetić, M. Zivanov, Michelino De Laurentiis et al.

Oct 29, 2025

Oncology and Therapy

HER2/EGFR in Cancer Research

article

A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program

Griet Hoste, Natalija Dedić Plavetić, M. Zivanov, Michelino De Laurentiis, Xavier González, Marija Križić, Tajana Silovski, Ángel Guerrero‐Zotano, Jeanne Suissa, Olivia Dialla, F. Beghdad, Olivier Romano, Ana Luisa Jiménez

October 29, 2025article en

Abstract

No abstract available for this paper.

Oncology and TherapyVol. 13(4)

University Hospital Centre Zagreb (HR), University of Zagreb (HR), Universitair Ziekenhuis Leuven (BE), Instituto Oncológico Dr. Rosell (ES), Fundación Instituto Valenciano de Oncología (ES), Complejo Hospitalario de Jaén (ES), Esteve Química (Spain) (ES), Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale" (IT), Pierre Fabre (France) (FR)

Openalex Percentile: Top 58%

HER2/EGFR in Cancer Research

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

A Retrospective Observational Study of Extended Adjuvant Neratinib for HER2-Positive Early-Stage Breast Cancer in a European Early Access Program — Griet Hoste, Natalija Dedić Plavetić, et al. · Oncology and Therapy (2025) | TGRS Research Map | TGRS